What's Happening?
Baker McKenzie has provided legal counsel to Bayer AG regarding the sale of its cancer treatment, Stivarga® (regorafenib), to Grünenthal. The agreement is valued at up to EUR 375 million. Stivarga® is an oral multikinase inhibitor used in the treatment of advanced
cancers, specifically for selected patient groups with metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. The medicine is approved and available in over 90 markets globally, having treated more than one million patients worldwide over the past decade. The transaction is contingent upon customary closing conditions, including necessary regulatory approvals, with closing anticipated in late 2026 or early 2027. Daniel Dehghanian, lead partner for the transaction at Baker McKenzie, expressed satisfaction in supporting Bayer AG in this significant transaction, which aligns with Bayer's value-oriented portfolio strategy.
Why It's Important?
This transaction highlights the ongoing strategic realignments within the pharmaceutical industry, particularly concerning high-value oncology assets. For Bayer AG, the divestment of Stivarga® is part of its broader portfolio strategy, allowing the company to optimize its focus and resources on other key areas. For Grünenthal, the acquisition strengthens its oncology portfolio and market presence, potentially expanding its reach in the global cancer treatment landscape. The involvement of a major law firm like Baker McKenzie underscores the complexity and cross-border nature of such deals, requiring extensive expertise in life sciences, M&A, antitrust, and intellectual property law across multiple jurisdictions, including the U.S. The sale of a widely used cancer treatment like Stivarga® also has implications for patient access and treatment continuity, although the transition to Grünenthal is expected to maintain availability in its existing markets.
What's Next?
The transaction is currently awaiting customary closing conditions, including regulatory approvals, which are expected to be finalized in late 2026 or early 2027. Following the closing, Grünenthal will assume responsibility for the Stivarga® product, integrating it into its existing portfolio and commercial operations. This will involve a transition period for manufacturing, distribution, and marketing activities. Regulatory bodies in the various markets where Stivarga® is available will need to approve the change in ownership to ensure continued patient access and compliance with pharmaceutical regulations. Both companies will likely focus on a smooth transition to minimize any disruption to patients and healthcare providers. Further strategic moves by both Bayer AG and Grünenthal in their respective portfolios may also be anticipated as they continue to refine their business strategies.
Beyond the Headlines
The sale of Stivarga® reflects a broader trend in the pharmaceutical sector where companies are increasingly divesting non-core assets to streamline operations and focus on areas of competitive advantage, often driven by pipeline innovation or market shifts. This strategic divestment can free up capital for research and development in emerging therapeutic areas or for other acquisitions that better align with long-term growth objectives. The deal also underscores the critical role of specialized legal counsel in navigating the intricate regulatory landscapes and intellectual property considerations inherent in global pharmaceutical transactions. The continued availability of Stivarga® under new ownership will be a key focus, ensuring that patients who rely on this treatment are not adversely affected by the corporate restructuring. This type of transaction also highlights the dynamic nature of drug ownership and the continuous evolution of the pharmaceutical market.
